To understand the human brain, an international consortium of scientists has created the most complete atlas of this organ to date. The map reveals the anatomy, the architecture of the tissues, how or where each cell is, their function, gene expression and regulation. On Oct. 12, 2023, Science and Science Advances published a group of 21 studies that unveiled the map of the human brain, as well as the brains of nonhuman primates and mice, cell by cell, for an adult model and for the different stages of development. Read More
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a modulator of CD47-SIRPα binding and can be targeted to achieve antitumor responses through myeloid checkpoint blockade. At the recent ESMO meeting in Madrid, researchers from Insilico Medicine Inc. reported the preclinical characterization of ISM-8207, a QPCTL inhibitor with activity against triple-negative breast cancer (TNBC) and diffuse large B-cell lymphoma (DLBCL). Read More
Mediar Therapeutics Inc. has announced the nomination of two first-in-class monoclonal antibody clinical candidates for fibrosis. The first, MTX-463, is designed to neutralize WISP-1 signaling. The second candidate, MTX-474, is designed to neutralize EphrinB2 signaling. Read More
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key regulator of immune signaling that supports proliferation and promotes metastasis while maintaining the tumor microenvironment under immunosuppression. Researchers from Exscientia plc and Evotec SE reported on the characterization of EXS-73565. Read More
Rarified Biosciences Inc. has reported mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, graft-vs.-host disease, systemic lupus erythematosus, scleroderma, psoriatic arthritis, primary sclerosing cholangitis, rheumatoid arthritis and inflammatory bowel disease. Read More
Ankyra Therapeutics Inc. has received approval of its IND application by the FDA and its clinical trial application (CTA) by Health Canada for its lead agent, ANK-101, a novel tumor-directed anchored immune medicine. Read More
Researchers from Guangdong University of Technology have reported the discovery of novel fibroblast growth factor receptor 1 (FGFR1) inhibitors as potential candidates for the treatment of glioblastoma multiforme (GBM). Read More
Appili Therapeutics Inc. has secured a commitment for the second stage of funding for ATI-1701 from the U.S. Air Force Academy (USAFA), who is working in partnership with the Defense Threat Reduction Agency, the funding agency. Read More
An Abbvie Inc. patent has disclosed thiazolo [5,4-b] pyridine compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL). Read More
Complement factor B (CFB) inhibitors are described in a Novartis AG patent and reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy and eye disorders, among others. Read More
Opna Bio AG recently provided findings from preclinical studies of novel dual E1A binding protein P300 (EP300) and CREB binding protein (CBP) inhibitors under investigation as potential anticancer agents. Read More
Sanofi SA has prepared and tested pyrazolopyrazinone compounds acting as cystine/glutamate transporter (solute carrier family 7 member 11; SLC7A11; xCT) inhibitors. Read More
Codagenix Inc. announced that the U.S. Department of Defense (DoD), through the U.S. Army Medical Research and Development Command and the U.S. Army Medical Research Acquisition Activity, has awarded the company $5.88 million to advance the development of its Codavax-Denv, a tetravalent live attenuated dengue vaccine program. Read More
Bloomsbury Genetic Therapies Ltd. has announced it received orphan drug designations from the FDA and the European Commission for BGT-INAD, an investigational gene therapy for the treatment of infantile neuroaxonal dystrophy (INAD). Read More
Additional early-stage research and drug discovery news in brief, from: Aviadobio, Meiragtx, Prime Medicine, Scynexis, Taysha Gene Therapies. Read More
